SCHEMBL22265486

SCHEMBL22265486

NC(=NO)c1ccc(Nc2cc(Br)ccc2Br)nc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 1/20 0.35
KDM1A O60341 1/20 0.33
NNMT P40261 1/20 0.33
IGF1R P08069 1/20 0.33
NPC1 O15118 4/20 0.33
RAB9A P51151 3/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
RXFP1 Q9HBX9 2/20 0.33
HCAR3 P49019 1/20 0.32
KDM4E B2RXH2 3/20 0.32
MAPT P10636 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
HPGD P15428 1/20 0.31
RECQL P46063 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
GSK3A P49840 1/20 0.31
CDK9 P50750 1/20 0.31
CDK5 Q00535 1/20 0.31
TAOK1 Q7L7X3 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22265485 1.00 F10 (0.35) F10KDM1ANNMTIGF1RNPC1
SCHEMBL22280469 0.75 CDK4 (0.33) MEN1KMT2AKDM4EMAPTHPGD
SCHEMBL22265582 0.73 F10 (0.49) F10NPC1RAB9AMEN1KMT2A
SCHEMBL22265584 0.73 F10 (0.49) F10NPC1RAB9AMEN1KMT2A
SCHEMBL1725522 0.70 NNMT (0.64) F10KDM1ANNMTNPC1RAB9A
SCHEMBL1725521 0.70 NNMT (0.64) F10KDM1ANNMTNPC1RAB9A
SCHEMBL22265325 0.70 HTT (0.38) IGF1RMEN1KMT2AGSK3ACDK9
SCHEMBL22280456 0.68 IGF1R (0.33) IGF1R
SCHEMBL14061764 0.68 RAB9A (0.40) KDM1ANNMTNPC1RAB9AMEN1
SCHEMBL14153259 0.68 RAB9A (0.40) KDM1ANNMTNPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12590083-B2 Inhibitors of spinster homolog 2 (SPNS2) for use in therapy UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2026-03-31 US disclosed
US-20220089581-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-03-24 US disclosed
EP-3914592-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY University of Virginia Patent Foundation (US) 2021-12-01 EP disclosed
WO-2020154431-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY LYNCH KEVIN R (US) 2020-07-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089581-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY SPNS2, SPCS2, SMN1; SMN2 F10 4513/4885KDM1A 4124/4885NNMT 657/4885
US-12590083-B2 Inhibitors of spinster homolog 2 (SPNS2) for use in therapy SPNS2, SLC20A2, S1PR2 F10 2211/4885KDM1A 4376/4885NNMT 4243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.